See more : PT Super Energy Tbk (SURE.JK) Income Statement Analysis – Financial Results
Complete financial analysis of ResMed Inc. (RMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ResMed Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Fame Productions, Inc. (FMPR) Income Statement Analysis – Financial Results
- Betta Pharmaceuticals Co., Ltd. (300558.SZ) Income Statement Analysis – Financial Results
- DaBomb Protein Biotech Corp. (6578.TWO) Income Statement Analysis – Financial Results
- Franchise Group, Inc. (FRGAP) Income Statement Analysis – Financial Results
- Sparc Technologies Limited (SPN.AX) Income Statement Analysis – Financial Results
ResMed Inc. (RMD)
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.69B | 4.22B | 3.58B | 3.20B | 2.96B | 2.61B | 2.34B | 2.07B | 1.84B | 1.68B | 1.55B | 1.51B | 1.37B | 1.24B | 1.09B | 920.74M | 835.40M | 716.33M | 607.00M | 425.51M | 339.34M | 273.57M | 204.08M | 155.16M | 115.62M | 88.60M | 66.50M | 49.20M | 34.60M | 23.50M | 13.90M | 7.70M |
| Cost of Revenue | 2.03B | 1.87B | 1.55B | 1.36B | 1.24B | 1.07B | 978.03M | 864.99M | 772.22M | 667.52M | 565.19M | 573.80M | 547.78M | 501.82M | 436.87M | 366.93M | 341.65M | 331.84M | 230.10M | 150.65M | 122.60M | 100.48M | 70.83M | 50.38M | 30.74M | 24.80M | 19.40M | 17.70M | 15.70M | 10.70M | 5.90M | 2.90M |
| Gross Profit | 2.66B | 2.36B | 2.02B | 1.84B | 1.72B | 1.54B | 1.36B | 1.20B | 1.07B | 1.01B | 989.79M | 940.66M | 820.74M | 741.33M | 655.48M | 553.80M | 493.75M | 384.49M | 376.90M | 274.86M | 216.74M | 173.09M | 133.25M | 104.78M | 84.87M | 63.80M | 47.10M | 31.50M | 18.90M | 12.80M | 8.00M | 4.80M |
| Gross Profit Ratio | 56.67% | 55.78% | 56.57% | 57.53% | 58.09% | 58.95% | 58.21% | 58.15% | 58.00% | 60.24% | 63.65% | 62.11% | 59.97% | 59.63% | 60.01% | 60.15% | 59.10% | 53.68% | 62.09% | 64.60% | 63.87% | 63.27% | 65.29% | 67.53% | 73.41% | 72.01% | 70.83% | 64.02% | 54.62% | 54.47% | 57.55% | 62.34% |
| Research & Development | 307.53M | 287.64M | 253.58M | 225.28M | 201.95M | 180.65M | 155.15M | 144.47M | 118.65M | 114.87M | 118.23M | 120.12M | 109.73M | 92.01M | 75.20M | 63.06M | 60.52M | 50.11M | 37.22M | 30.01M | 26.17M | 20.53M | 14.91M | 11.15M | 8.50M | 6.50M | 5.00M | 3.80M | 2.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.37M | 553.97M | 488.06M | 478.63M | 450.41M | 430.80M | 401.62M | 372.25M | 331.86M | 289.88M | 278.09M | 237.33M | 200.17M | 135.70M | 104.71M | 85.31M | 64.48M | 49.91M | 36.99M | 27.40M | 21.10M | 16.80M | 11.10M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.46M | -6.00M | 0.00 | 0.00 | 0.00 | -1.00M | -3.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 917.14M | 874.00M | 739.37M | 670.39M | 676.69M | 645.01M | 600.37M | 553.97M | 482.59M | 472.63M | 450.41M | 430.80M | 401.62M | 371.25M | 328.86M | 289.88M | 278.09M | 237.33M | 200.17M | 135.70M | 104.71M | 85.31M | 64.48M | 49.91M | 36.99M | 27.40M | 21.10M | 16.80M | 11.10M | 9.40M | 6.40M | 3.90M |
| Other Expenses | 110.75M | -5.71M | 31.08M | 31.08M | 30.09M | 74.94M | -8.54M | 4.10M | 4.96M | 6.25M | 884.00K | -2.19M | 8.46M | 10.15M | 8.04M | 7.06M | 9.79M | 6.90M | 7.09M | 1.37M | 500.00K | 0.00 | 104.67M | 0.00 | 6.25M | 4.60M | 3.70M | 2.60M | 1.30M | 600.00K | 300.00K | 200.00K |
| Operating Expenses | 1.34B | 1.20B | 1.02B | 926.75M | 908.73M | 900.60M | 801.90M | 745.01M | 625.17M | 596.16M | 578.37M | 585.83M | 525.33M | 473.40M | 412.10M | 359.99M | 348.40M | 294.33M | 244.47M | 167.09M | 131.38M | 105.85M | 184.06M | 61.06M | 51.73M | 38.50M | 29.80M | 23.20M | 15.20M | 10.00M | 6.70M | 4.10M |
| Cost & Expenses | 3.37B | 3.07B | 2.58B | 2.28B | 2.15B | 1.97B | 1.78B | 1.61B | 1.40B | 1.26B | 1.14B | 1.16B | 1.07B | 975.22M | 848.98M | 726.92M | 690.05M | 626.17M | 474.57M | 317.73M | 253.98M | 206.33M | 254.89M | 111.44M | 82.48M | 63.30M | 49.20M | 40.90M | 30.90M | 20.70M | 12.60M | 7.00M |
| Interest Income | 0.00 | 47.38M | 22.31M | 362.00K | 1.02M | 2.30M | 16.38M | 17.09M | 16.86M | 26.21M | 31.24M | 38.87M | 33.87M | 27.80M | 16.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 45.71M | 47.38M | 22.31M | 23.99M | 40.38M | 36.16M | 28.36M | 28.24M | 11.21M | 5.78M | 6.13M | 6.39M | 4.79M | 1.76M | 10.06M | 10.06M | 10.06M | 1.32M | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 216.21M | 196.52M | 193.84M | 191.52M | 181.37M | 150.80M | 119.96M | 112.16M | 86.85M | 73.06M | 9.73M | 10.14M | 13.97M | 10.15M | 8.04M | 7.06M | 59.49M | 48.14M | 41.62M | 29.13M | 17.87M | 12.58M | 9.97M | 8.45M | 6.25M | 4.60M | 3.70M | 2.60M | 1.30M | 600.00K | 300.00K | 200.00K |
| EBITDA | 1.53B | 1.36B | 1.18B | 1.10B | 990.43M | 705.80M | 680.22M | 568.89M | 522.72M | 482.29M | 484.87M | 469.79M | 422.59M | 374.32M | 322.15M | 190.31M | 204.83M | 90.16M | 174.04M | 136.90M | 85.36M | 79.82M | -40.84M | 52.16M | 39.39M | 29.90M | 21.00M | 10.90M | 4.90M | 3.40M | 1.60M | 900.00K |
| EBITDA Ratio | 32.73% | 31.72% | 33.37% | 34.80% | 33.47% | 32.36% | 29.85% | 29.02% | 29.40% | 29.44% | 27.49% | 24.10% | 22.68% | 23.31% | 22.73% | 22.07% | 24.47% | 19.12% | 28.86% | 34.72% | 30.28% | 28.29% | -21.95% | 43.70% | 33.87% | 35.44% | 33.53% | 16.46% | 5.78% | 10.21% | 7.91% | 3.90% |
| Operating Income | 1.32B | 1.13B | 1.00B | 903.68M | 809.66M | 579.26M | 541.83M | 425.80M | 428.95M | 409.24M | 405.09M | 354.82M | 294.41M | 266.92M | 240.38M | 190.31M | 142.97M | 90.16M | 131.30M | 97.35M | 85.36M | 67.24M | -51.16M | 26.04M | 33.14M | 25.30M | 17.30M | 8.30M | 3.70M | 2.80M | 1.30M | 700.00K |
| Operating Income Ratio | 28.17% | 26.80% | 27.96% | 28.27% | 27.38% | 22.22% | 23.15% | 20.60% | 23.33% | 24.38% | 26.05% | 23.43% | 21.51% | 21.47% | 22.01% | 20.67% | 17.11% | 12.59% | 21.63% | 22.88% | 25.16% | 24.58% | -25.07% | 16.78% | 28.66% | 28.56% | 26.02% | 16.87% | 10.69% | 11.91% | 9.35% | 9.09% |
| Total Other Income/Expenses | -55.10M | -30.21M | -39.80M | -20.02M | -76.57M | -60.42M | -20.52M | -7.06M | 10.61M | 26.68M | 25.99M | 30.30M | 37.54M | 36.78M | 20.21M | 11.37M | 14.89M | 7.81M | 2.09M | -727.00K | -693.00K | -113.00K | 105.75M | 1.27M | 1.03M | -700.00K | -1.20M | 2.80M | 2.90M | 900.00K | 500.00K | 500.00K |
| Income Before Tax | 1.26B | 1.10B | 960.48M | 883.66M | 733.09M | 518.85M | 521.31M | 418.74M | 439.57M | 435.92M | 431.08M | 385.12M | 331.95M | 303.71M | 260.59M | 201.68M | 157.86M | 97.97M | 133.39M | 96.63M | 84.67M | 67.13M | 54.59M | 27.31M | 34.17M | 24.60M | 16.10M | 11.10M | 6.60M | 3.70M | 1.80M | 1.20M |
| Income Before Tax Ratio | 27.00% | 26.09% | 26.84% | 27.64% | 24.79% | 19.91% | 22.28% | 20.26% | 23.91% | 25.96% | 27.72% | 25.43% | 24.26% | 24.43% | 23.86% | 21.90% | 18.90% | 13.68% | 21.98% | 22.71% | 24.95% | 24.54% | 26.75% | 17.60% | 29.55% | 27.77% | 24.21% | 22.56% | 19.08% | 15.74% | 12.95% | 15.58% |
| Income Tax Expense | 243.85M | 204.11M | 181.05M | 409.16M | 111.41M | 114.26M | 205.72M | 76.46M | 87.16M | 83.03M | 85.81M | 77.99M | 77.10M | 76.72M | 70.50M | 55.24M | 47.55M | 31.67M | 45.18M | 31.84M | 27.38M | 21.40M | 17.09M | 15.68M | 11.94M | 8.50M | 5.50M | 3.60M | 2.10M | 900.00K | 600.00K | 400.00K |
| Net Income | 1.02B | 897.56M | 779.44M | 474.51M | 621.67M | 404.59M | 315.59M | 342.28M | 352.41M | 352.89M | 345.27M | 307.13M | 254.85M | 226.99M | 190.09M | 146.45M | 110.30M | 66.30M | 88.21M | 64.79M | 57.28M | 45.73M | 37.51M | 11.63M | 22.23M | 16.10M | 10.60M | 7.50M | 4.50M | 2.80M | 1.20M | 800.00K |
| Net Income Ratio | 21.79% | 21.25% | 21.78% | 14.84% | 21.02% | 15.52% | 13.49% | 16.56% | 19.17% | 21.02% | 22.20% | 20.28% | 18.62% | 18.26% | 17.40% | 15.91% | 13.20% | 9.26% | 14.53% | 15.23% | 16.88% | 16.72% | 18.38% | 7.50% | 19.22% | 18.17% | 15.94% | 15.24% | 13.01% | 11.91% | 8.63% | 10.39% |
| EPS | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 | 2.51 | 2.51 | 2.44 | 2.15 | 1.75 | 1.49 | 1.26 | 0.97 | 0.72 | 0.43 | 0.61 | 0.47 | 0.43 | 0.35 | 0.29 | 0.09 | 0.19 | 0.14 | 0.09 | 0.06 | 0.04 | 0.04 | 0.02 | 0.02 |
| EPS Diluted | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 | 2.49 | 2.47 | 2.39 | 2.10 | 1.71 | 1.44 | 1.23 | 0.95 | 0.70 | 0.43 | 0.58 | 0.46 | 0.41 | 0.33 | 0.28 | 0.09 | 0.17 | 0.13 | 0.09 | 0.06 | 0.04 | 0.04 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 147.02M | 146.77M | 146.07M | 145.31M | 144.34M | 143.11M | 142.76M | 141.36M | 140.24M | 140.47M | 141.47M | 142.95M | 145.90M | 152.47M | 150.91M | 151.26M | 154.76M | 153.42M | 144.61M | 137.29M | 134.78M | 132.22M | 128.70M | 124.52M | 120.61M | 117.66M | 116.16M | 117.07M | 112.50M | 70.00M | 53.33M | 48.00M |
| Weighted Avg Shares Out (Dil) | 147.55M | 147.46M | 147.04M | 146.45M | 145.65M | 144.48M | 143.99M | 142.45M | 141.67M | 142.69M | 144.36M | 146.41M | 149.32M | 157.20M | 155.10M | 154.23M | 157.42M | 156.51M | 154.32M | 149.88M | 140.50M | 137.76M | 136.32M | 133.94M | 129.21M | 124.27M | 120.28M | 117.07M | 112.50M | 70.00M | 53.33M | 48.00M |
4 Medical Product Stocks to Buy From a Prospective Industry
Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed
Here's Why ResMed (RMD) is a Strong Momentum Stock
My Top 15 High-Growth Dividend Stocks For December 2024
RMD vs. LMAT: Which Stock Is the Better Value Option?
5 Top-Ranked Dividend Growth Stocks for Your Portfolio
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
Here's Why You Should Add RMD Stock to Your Portfolio Now
5 Dividend Growth Stocks to Buy on Trump Win & Fed Rate Cut
Source: https://incomestatements.info
Category: Stock Reports